Rithron XR Approval Is Part Of Larger U.S. Vascular Intervention Strategy
This article was originally published in The Gray Sheet
Executive Summary
FDA approval of Biotronik's Rithron XR coronary stent marks a first step in the firm's long-term strategy to enter the U.S. vascular intervention market